ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices. Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems. This discontinuation follows several U.S. Food and Drug Administration (FDA) mandated CPAP recalls over the past several years adversely impacting an estimated 4 million patients.
Related news for (OSA)
- Cosa Resources Announces Voting Results from Its Annual General Meeting
- Cosa Resources Enters into Option Agreement for the Astro Uranium Project, Athabasca Basin, Saskatchewan
- Global Uranium Enters Into Option Agreement With Cosa Resources for the Astro Uranium Project in the Athabasca Basin, Saskatchewan, Canada
- Cosa Resources Announces Drilling Plans for Murphy Lake North Uranium Project, Athabasca Basin, Saskatchewan
- Cosa Resources Reports Uranium Assays from the 100% Owned Ursa Project, Athabasca Basin, Saskatchewan